Hellow guys, Welcome to my website, and you are watching The genetic complexity of CML beyond BCR-ABL1 & the clinical impact of additional abnormalities. and this vIdeo is uploaded by VJHemOnc – Video Journal of Hematology & HemOnc at 2023-10-09T04:46:53-07:00. We are pramote this video only for entertainment and educational perpose only. So, I hop you like our website.
| Name | The genetic complexity of CML beyond BCR-ABL1 & the clinical impact of additional abnormalities |
| Video Uploader | Video From VJHemOnc – Video Journal of Hematology & HemOnc |
| Upload Date | This Video Uploaded At 09-10-2023 07:46:53 |
| Video Discription | David Ross, MBBS, PhD, FRACP, FRCPA, Royal Adelaide Hospital and Institute, Adelaide, Australia, discusses the genetic complexity of chronic myeloid leukemia (CML) beyond BCR-ABL1, and talks on the clinical significance of additional genetic abnormalities such as ASXL1 mutation in this disease. Prof. Ross also comments on the prognostic effect of Philadelphia-associated rearrangements. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved. |
| Category | Education |
| Tags | Speaker: David Ross | Institution: Royal Adelaide Hospital and Institute | Event: SOHO 2023 | Format: Interview | Subject: Leukemia | Subject: Chronic Myeloid Leukemia | Field: Perspectives | Field: Disease Biology | Field: Treatment | Medicines: Imatinib | Medicines: Nilotinib | Trial: TIGER | NCT01657604 | BCR-ABL1 | ASXL1 | Philadelphia chromosome | TKIs |
